Clinical Trial Results:
Efficacy and safety of tianeptine oral administration (25 to 50 mg/day) in elderly patients suffering from Major Depressive Disorder.
A 8-week, randomized, double-blind, flexible-dose, parallel groups, placebo-controlled, international, multicentre study with escitalopram as active control, followed by an optional double-blind extension treatment period of 16 weeks.
Summary
|
|
EudraCT number |
2012-005612-26 |
Trial protocol |
SK FI EE BG |
Global end of trial date |
13 Jan 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
15 Oct 2016
|
First version publication date |
15 Oct 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
CL3-01574-237
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Institut de Recherches Internationales Servier
|
||
Sponsor organisation address |
50, rue Carnot, Suresnes, France,
|
||
Public contact |
Clinical Studies Department, Institut de Recherches Internationales Servier (I.R.I.S.), +33 1 55 72 43 66, clinicaltrials@servier.com
|
||
Scientific contact |
Clinical Studies Department, Institut de Recherches Internationales Servier (I.R.I.S.), +33 1 55 72 43 66, clinicaltrials@servier.com
|
||
Sponsor organisation name |
Institut de Recherches Internationales Servier
|
||
Sponsor organisation address |
50, rue Carnot, Suresnes, France, 92284
|
||
Public contact |
Clinical Studies Department, Institut de Recherches Internationales Servier (I.R.I.S.), 33 1 55724366, clinicaltrials@servier.com
|
||
Scientific contact |
Clinical Studies Department, Institut de Recherches Internationales Servier (I.R.I.S.), 33 1 55724366, clinicaltrials@servier.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
13 Jan 2016
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
13 Jan 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
13 Jan 2016
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To demonstrate the antidepressant efficacy of an 8-week tianeptine oral administration in elderly out-patients suffering from Major Depressive Disorder compared to placebo. The assay sensitivity will be evaluated comparing escitalopram to placebo.
|
||
Protection of trial subjects |
This study was conducted in accordance with Good Clinical Practice standards, ethical principles stated in the Declaration of Helsinki and applicable regulatory requirements. After the subject has ended his/her participation in the trial, the investigator provided appropriate medication and/or arranged access to appropriate care for the patient.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
28 Oct 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
France: 12
|
||
Country: Number of subjects enrolled |
Romania: 39
|
||
Country: Number of subjects enrolled |
Malaysia: 3
|
||
Country: Number of subjects enrolled |
Mexico: 43
|
||
Country: Number of subjects enrolled |
Korea, Republic of: 23
|
||
Country: Number of subjects enrolled |
Poland: 10
|
||
Country: Number of subjects enrolled |
Slovakia: 37
|
||
Country: Number of subjects enrolled |
Bulgaria: 26
|
||
Country: Number of subjects enrolled |
Estonia: 29
|
||
Country: Number of subjects enrolled |
Finland: 89
|
||
Worldwide total number of subjects |
311
|
||
EEA total number of subjects |
242
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
310
|
||
85 years and over |
1
|
|
|||||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||||
Recruitment details |
Investigators were General Practitioners, specialists in psychiatry. | ||||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||||
Screening details |
Male or female out-patients, ≥ 65-year old, fulfilling DSM-IV-TR criteria for a moderate to severe episode of a recurrent major depressive disorder, with Hamilton depression rating scale 17 items (HAM-D) total score ≥ 22 and clinical global impression (CGI) severity of illness score ≥ 4. | ||||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||||
Period 1 title |
Double-blind treatment period of 8 weeks
|
||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||
Arm title
|
Tianeptine | ||||||||||||||||||||||||||||||||
Arm description |
All patients received 25 mg/day of tianeptine during the first 2 weeks of treatment. At W2, patients with insufficient clinical improvement according to a blind pre-determined clinical improvement criterion received 50 mg/day. After W2, the 25 mg or 50 mg dose was maintained up to W8. | ||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Tianeptine
|
||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||
Dosage and administration details |
Capsules of 12.5 or 25 mg of tianeptine, taken orally twice daily (one capsule in the morning and one capsule in the evening before meals).
For patients receiving tianeptine 25 mg daily at inclusion (W0), a potential adjustment to 50 mg daily might occur at Week-2 (W2) using pre-determined fixed criterion, in double-blind conditions (neither the investigator, neither the sponsor staff, nor the patients knew whether the dose had been increased) in case of insufficient improvement of depressive symptoms. Patients with sufficient improvement remained on tianeptine 25 mg daily. During tapering period, dose of tianeptine was unchanged.
|
||||||||||||||||||||||||||||||||
Arm title
|
Escitalopram | ||||||||||||||||||||||||||||||||
Arm description |
All patients received a starting dosage of 5 mg/day during the first 2 weeks of treatment. At W2, all patients increased to 10 mg/day (mandatory adjustment). At the end of the study or in case of premature study withdrawal after W2, all patients received 5 mg/day for the last week (tapering period). | ||||||||||||||||||||||||||||||||
Arm type |
Active control to assay sensitivity | ||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Escitalopram
|
||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||
Dosage and administration details |
Capsule of 5 mg or 10 mg of escitalopram or placebo, taken orally twice daily (one escitalopram capsule in the morning and one placebo capsule in the evening before meals). Patients received 5 mg daily from W0 to W2, then 10 mg daily from W2. A one-week tapering period at 5 mg/day was planned to avoid possible withdrawal reactions.
|
||||||||||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||||||||||
Arm description |
Potential or mandatory dose increase (tianeptine and escitalopram groups, respectively) and dose decrease (escitalopram group) were in blind condition. | ||||||||||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||
Dosage and administration details |
One capsule taken orally twice daily (one capsule in the morning and one capsule in the evening before meals).
|
||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Period 2
|
|||||||||||||||||||||||||||||||||
Period 2 title |
Optional extension period of 16 weeks
|
||||||||||||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||
Arm title
|
Tianeptine | ||||||||||||||||||||||||||||||||
Arm description |
To continue in the optional extension period, patients had to be responder to treatment according to HAM-D total score at W8 (decrease from baseline in HAM-D total score of at least 50%). At W12, only patients with a Clinical Global Impression (CGI) global improvement (item 2) ≤ 2 could continue in the optional extension period up to W24. | ||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Tianeptine
|
||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||
Dosage and administration details |
Capsules of 12.5 or 25 mg of tianeptine, taken orally twice daily (one capsule in the morning and one capsule in the evening before meals).
The tianeptine dose fixed in blind condition at W2 according to clinical improvement (25 mg/day or 50 mg/day)remained unchanged during the optional extension period. The dose of tianeptine was unchanged during the tapering period (end of the study or in case of premature study discontinuation).
|
||||||||||||||||||||||||||||||||
Arm title
|
Escitalopram | ||||||||||||||||||||||||||||||||
Arm description |
To continue in the optional extension period, patients had to be responder to treatment according to HAM-D total score at W8 (decrease from baseline in HAM-D total score of at least 50%). At W12, only patients with a Clinical Global Impression (CGI) global improvement (item 2) ≤ 2 could continue in the optional extension period up to W24. | ||||||||||||||||||||||||||||||||
Arm type |
Active control to assay sensitivity | ||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Escitalopram
|
||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||
Dosage and administration details |
Capsule of 5 mg or 10 mg of escitalopram or placebo, taken orally twice daily (one escitalopram capsule in the morning and one placebo capsule in the evening before meals).
During the optional extension period, the patients received 10 mg/day. A one-week tapering period at 5 mg/day was planned to avoid possible withdrawal reactions at the end of the study or in case of premature study discontinuation.
|
||||||||||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||||||||||
Arm description |
To continue in the optional extension period, patients had to be responder to treatment according to HAM-D total score at W8 (decrease from baseline in HAM-D total score of at least 50%). At W12, only patients with a Clinical Global Impression (CGI) global improvement (item 2) ≤ 2 could continue in the optional extension period up to W24. | ||||||||||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||
Dosage and administration details |
One capsule taken orally twice daily (one capsule in the morning and one capsule in the evening before meals).
|
||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Notes [1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period. Justification: To continue in the optional extension period, patients had to be responder to treatment according to HAM-D total score at W8 (decrease from baseline in HAM-D total score of at least 50%). At W12, only patients with a Clinical Global Impression (CGI) global improvement (item 2) ≤ 2 could continue in the optional extension period up to W24. 20 patients in the tianeptine group, 13 patients in the escitalopram group and 34 patients in the placebo group did not enter the optional extension period. |
|||||||||||||||||||||||||||||||||
Period 3
|
|||||||||||||||||||||||||||||||||
Period 3 title |
Tapering period of 1 week
|
||||||||||||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||
Arm title
|
Tianeptine | ||||||||||||||||||||||||||||||||
Arm description |
During tapering period, dose of tianeptine was unchanged. The tapering period was planned after W2 to avoid discontinuation symptoms of escitalopram as recommended in the SmPC of escitalopram. | ||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Tianeptine
|
||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||
Dosage and administration details |
Capsules of 12.5 or 25 mg of tianeptine, taken orally twice daily (one capsule in the morning and one capsule in the evening before meals).
The tianeptine dose fixed in blind condition at W2 according to clinical improvement (25 mg/day or 50 mg/day) remained unchanged during the tapering period (end of the study or in case of premature study discontinuation).
|
||||||||||||||||||||||||||||||||
Arm title
|
Escitalopram | ||||||||||||||||||||||||||||||||
Arm description |
The tapering period was planned after W2 to avoid discontinuation symptoms of escitalopram as recommended in the SmPC of escitalopram. Only escitalopram dose was decreased during this period. | ||||||||||||||||||||||||||||||||
Arm type |
Active control to assay sensitivity | ||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Escitalopram
|
||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||
Dosage and administration details |
Capsule of 5 mg or 10 mg of escitalopram or placebo, taken orally twice daily (one escitalopram capsule in the morning and one placebo capsule in the evening before meals).
From W2, all patients received 10 mg/day. After W2, a one-week tapering period at 5 mg/day was planned to avoid possible withdrawal reactions.
|
||||||||||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||||||||||
Arm description |
The tapering period planned to follow the SmPC of escitalopram was in blind condition. | ||||||||||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||
Dosage and administration details |
One capsule taken orally twice daily (one capsule in the morning and one capsule in the evening before meals).
|
||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Tianeptine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
All patients received 25 mg/day of tianeptine during the first 2 weeks of treatment. At W2, patients with insufficient clinical improvement according to a blind pre-determined clinical improvement criterion received 50 mg/day. After W2, the 25 mg or 50 mg dose was maintained up to W8. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Escitalopram
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
All patients received a starting dosage of 5 mg/day during the first 2 weeks of treatment. At W2, all patients increased to 10 mg/day (mandatory adjustment). At the end of the study or in case of premature study withdrawal after W2, all patients received 5 mg/day for the last week (tapering period). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Potential or mandatory dose increase (tianeptine and escitalopram groups, respectively) and dose decrease (escitalopram group) were in blind condition. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Tianeptine
|
||
Reporting group description |
All patients received 25 mg/day of tianeptine during the first 2 weeks of treatment. At W2, patients with insufficient clinical improvement according to a blind pre-determined clinical improvement criterion received 50 mg/day. After W2, the 25 mg or 50 mg dose was maintained up to W8. | ||
Reporting group title |
Escitalopram
|
||
Reporting group description |
All patients received a starting dosage of 5 mg/day during the first 2 weeks of treatment. At W2, all patients increased to 10 mg/day (mandatory adjustment). At the end of the study or in case of premature study withdrawal after W2, all patients received 5 mg/day for the last week (tapering period). | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Potential or mandatory dose increase (tianeptine and escitalopram groups, respectively) and dose decrease (escitalopram group) were in blind condition. | ||
Reporting group title |
Tianeptine
|
||
Reporting group description |
To continue in the optional extension period, patients had to be responder to treatment according to HAM-D total score at W8 (decrease from baseline in HAM-D total score of at least 50%). At W12, only patients with a Clinical Global Impression (CGI) global improvement (item 2) ≤ 2 could continue in the optional extension period up to W24. | ||
Reporting group title |
Escitalopram
|
||
Reporting group description |
To continue in the optional extension period, patients had to be responder to treatment according to HAM-D total score at W8 (decrease from baseline in HAM-D total score of at least 50%). At W12, only patients with a Clinical Global Impression (CGI) global improvement (item 2) ≤ 2 could continue in the optional extension period up to W24. | ||
Reporting group title |
Placebo
|
||
Reporting group description |
To continue in the optional extension period, patients had to be responder to treatment according to HAM-D total score at W8 (decrease from baseline in HAM-D total score of at least 50%). At W12, only patients with a Clinical Global Impression (CGI) global improvement (item 2) ≤ 2 could continue in the optional extension period up to W24. | ||
Reporting group title |
Tianeptine
|
||
Reporting group description |
During tapering period, dose of tianeptine was unchanged. The tapering period was planned after W2 to avoid discontinuation symptoms of escitalopram as recommended in the SmPC of escitalopram. | ||
Reporting group title |
Escitalopram
|
||
Reporting group description |
The tapering period was planned after W2 to avoid discontinuation symptoms of escitalopram as recommended in the SmPC of escitalopram. Only escitalopram dose was decreased during this period. | ||
Reporting group title |
Placebo
|
||
Reporting group description |
The tapering period planned to follow the SmPC of escitalopram was in blind condition. |
|
|||||||||||||||||
End point title |
HAM-D total score (main analysis) | ||||||||||||||||
End point description |
The treatment difference between tianeptine and placebo was studied in the FAS from the HAM-D total score expressed in terms of change from baseline to W8, using a two-way analysis of covariance (ANCOVA) model (including the three treatment groups).
Analysis include the fixed, categorical effects of treatment, the random categorical effect of centre as well as the continuous, fixed covariate of baseline HAM-D total score.
Missing data at W8 were imputed using LOCF approach.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
The primary efficacy criterion was the HAM-D 17 total score expressed mainly in term of change from baseline to W8.
|
||||||||||||||||
|
|||||||||||||||||
Notes [1] - Full analysis Set Missing data at W8 were imputed using the Last Observation Carried Forward (LOCF) [2] - Full Analysis Set Missing data at W8 were imputed using the Last Observation Carried Forward (LOCF) [3] - Full Analysis Set Missing data at W8 were imputed using the Last Observation Carried Forward (LOCF) |
|||||||||||||||||
Statistical analysis title |
Main analysis (Tianeptine versus placebo) | ||||||||||||||||
Statistical analysis description |
Analysis of covariance model on factors treatment and centre (random effect) with baseline HAM-D total score as covariate.
|
||||||||||||||||
Comparison groups |
Tianeptine v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
211
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||
Method |
ANCOVA | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
3.84
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
2.17 | ||||||||||||||||
upper limit |
5.51 | ||||||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||||||
Dispersion value |
0.85
|
||||||||||||||||
Statistical analysis title |
Assay sensitivity (escitalopram vs placebo) | ||||||||||||||||
Statistical analysis description |
Escitalopram was compared to placebo using strictly the same strategy as for the comparison between tianeptine and placebo
|
||||||||||||||||
Comparison groups |
Escitalopram v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
204
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [4] | ||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||
Method |
ANCOVA | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
4.09
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
2.39 | ||||||||||||||||
upper limit |
5.79 | ||||||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||||||
Dispersion value |
0.86
|
||||||||||||||||
Notes [4] - Analysis of covariance model on factors treatment and centre (random effect) with baseline HAM-D total score as covariate. |
|
|||||||||||||||||
End point title |
HAM-D total score (sensitivity analysis) | ||||||||||||||||
End point description |
Sensitivity analysis to the method of handling missing data: MMRM analysis in all patients of the FAS.
Tianeptine and escitalopram were compared to placebo in the FAS on the change from baseline to W8 of HAM-D total score, using a restricted maximum likelihood (REML)-based, mixed-effects repeated measures approach (MMRM) using all the longitudinal observations at each post-baseline visit (W2, W4, W6 and W8) expressed as change from baseline. Analysis included the fixed, categorical effects of treatment, visit and treatment-by-visit interaction, the random categorical effect of centre as well as the continuous, fixed covariate of baseline.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
The primary efficacy criterion was the HAM-D 17 total score expressed mainly in term of change from baseline to W8.
|
||||||||||||||||
|
|||||||||||||||||
Notes [5] - FAS patients with HAM-D total score both at baseline and W8 [6] - FAS patients with HAM-D total score both at baseline and W8 [7] - FAS patients with HAM-D total score both at baseline and W8 |
|||||||||||||||||
Statistical analysis title |
Sensitivity analysis (Tianeptine vs placebo) | ||||||||||||||||
Statistical analysis description |
Maximum likelihood (REML)-based, mixed-effects repeated measures approach (MMRM) using all the longitudinal observations at each post-baseline visit (W2, W4, W6 and W8) expressed as change from baseline.
Analysis included the fixed, categorical effects of treatment, visit and treatment-by-visit interaction, the random categorical effect of centre as well as the continuous, fixed covariate of baseline.
|
||||||||||||||||
Comparison groups |
Tianeptine v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
195
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
3.65
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
1.84 | ||||||||||||||||
upper limit |
5.47 | ||||||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||||||
Dispersion value |
0.92
|
||||||||||||||||
Statistical analysis title |
Sensitivity analysis (escitalopram vs placebo) | ||||||||||||||||
Comparison groups |
Escitalopram v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
186
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||
Point estimate |
4.53
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
2.67 | ||||||||||||||||
upper limit |
6.4 | ||||||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||||||
Dispersion value |
0.95
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse events were reported at each visit over the whole duration of the study. Adverse events presented here are those reported during the W0-W25 treatment period.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
18.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Tianeptine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Escitalopram
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 3.5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
16 Dec 2013 |
Applicable to all countries.
It mainly concerned the implementation of the changes related to the revision (dated 02 October 2013) of escitalopram SmPC. According to this revision, one non selection or non-inclusion criterion was added for patients with angle-close glaucoma or history of glaucoma and a caution was warranted for concomitant use of medicinal products inducing hypokalaemia/hypomagnesaemia as these conditions increased the risk of malignant arrhythmias with study drugs.
One other change implemented with this amendment was the update of the Declaration of Helsinki to be in accordance with the revised version of Fortaleza, October 2013.
Secondary objectives of this amendment were to complete or correct the following information:
- Conditions of storage of the treatments.
- Antihistamines with central effects in the list of forbidden treatments due to their possible action on the central nervous system.
- Doses of the benzodiazepines authorized as concomitant medications (equivalent to 10 mg of diazepam).
- Collected blood volumes and interpretation of hepatitis B serology status.
- Use of the computerized medical file.
- MINI and CGI scales according to the final e-CRF format. |
||
22 Oct 2014 |
Three countries participating to the study were added (Bulgaria, Poland and South Africa) and one country was removed (Argentina). |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |